@IndexInvestor
Sheba 2 result:
" the six patients were heavily pre-treated and had received a median of four prior lines of AML treatment (range 2 - 8)."
"...Three patients 1 CR and 2 PR were bridged..transplant.Of note: these three patients had all received less than five prior line of treatment...."
Logically from the above notes, I would assume that in EMD AML trial which RAC has totally control including the right to select the most suitable clinical patients for this trial and therefore the patients with 2 pre-treated or less would be ideal
AIMO
RAC - Charts & Price Action, page-13050
-
- There are more pages in this discussion • 8,746 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |